Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692046 | 1.00 | DGAT1 (0.44) | DGAT1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL22692094 | 1.00 | DGAT1 (0.44) | DGAT1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL22692135 | 0.93 | DGAT1 (0.45) | DGAT1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL22709341 | 0.93 | DGAT1 (0.41) | DGAT1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL22692134 | 0.93 | DGAT1 (0.45) | DGAT1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL22709879 | 0.93 | DGAT1 (0.41) | DGAT1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL22709891 | 0.88 | BACE1 (0.45) | DGAT1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL29423693 | 0.88 | BACE1 (0.45) | DGAT1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL22709347 | 0.85 | HDAC9 (0.38) | HTR2C | |
| SCHEMBL22692086 | 0.83 | FFAR4 (0.37) | DGAT1NPSR1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227738-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-07-21 | — | — | US | disclosed |
| WO-2022115439-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972978-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020236940-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227738-A1 | KRAS G12C INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | DGAT1 1064/4885NPSR1 4763/4885MEN1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.